nodes	percent_of_prediction	percent_of_DWPC	metapath
Fludrocortisone—Skin hyperpigmentation—Mechlorethamine—lymphatic system cancer	0.0377	0.0377	CcSEcCtD
Fludrocortisone—Muscle atrophy—Vincristine—lymphatic system cancer	0.0376	0.0376	CcSEcCtD
Fludrocortisone—Aseptic necrosis—Methotrexate—lymphatic system cancer	0.0373	0.0373	CcSEcCtD
Fludrocortisone—Skin striae—Bleomycin—lymphatic system cancer	0.0335	0.0335	CcSEcCtD
Fludrocortisone—Petechiae—Mechlorethamine—lymphatic system cancer	0.0272	0.0272	CcSEcCtD
Fludrocortisone—Osteoporosis—Fludarabine—lymphatic system cancer	0.0259	0.0259	CcSEcCtD
Fludrocortisone—Amenorrhoea—Mechlorethamine—lymphatic system cancer	0.0255	0.0255	CcSEcCtD
Fludrocortisone—Optic neuritis—Fludarabine—lymphatic system cancer	0.0236	0.0236	CcSEcCtD
Fludrocortisone—Trauma—Bleomycin—lymphatic system cancer	0.0223	0.0223	CcSEcCtD
Fludrocortisone—Intracranial pressure increased—Carmustine—lymphatic system cancer	0.0222	0.0222	CcSEcCtD
Fludrocortisone—Impaired healing—Carmustine—lymphatic system cancer	0.0215	0.0215	CcSEcCtD
Fludrocortisone—Thrombophlebitis—Mechlorethamine—lymphatic system cancer	0.0188	0.0188	CcSEcCtD
Fludrocortisone—Skin hyperpigmentation—Bleomycin—lymphatic system cancer	0.0179	0.0179	CcSEcCtD
Fludrocortisone—Skin hyperpigmentation—Carmustine—lymphatic system cancer	0.0156	0.0156	CcSEcCtD
Fludrocortisone—Neoplasm—Teniposide—lymphatic system cancer	0.0149	0.0149	CcSEcCtD
Fludrocortisone—Oesophagitis—Fludarabine—lymphatic system cancer	0.0133	0.0133	CcSEcCtD
Fludrocortisone—Diabetic—Methotrexate—lymphatic system cancer	0.0129	0.0129	CcSEcCtD
Fludrocortisone—Cardiac failure congestive—Fludarabine—lymphatic system cancer	0.0116	0.0116	CcSEcCtD
Fludrocortisone—Osteonecrosis—Methotrexate—lymphatic system cancer	0.0115	0.0115	CcSEcCtD
Fludrocortisone—Haemoglobin—Mechlorethamine—lymphatic system cancer	0.0113	0.0113	CcSEcCtD
Fludrocortisone—Haemorrhage—Mechlorethamine—lymphatic system cancer	0.0112	0.0112	CcSEcCtD
Fludrocortisone—Petechiae—Mitoxantrone—lymphatic system cancer	0.0105	0.0105	CcSEcCtD
Fludrocortisone—Impaired healing—Methotrexate—lymphatic system cancer	0.00995	0.00995	CcSEcCtD
Fludrocortisone—Contusion—Mitoxantrone—lymphatic system cancer	0.0099	0.0099	CcSEcCtD
Fludrocortisone—Amenorrhoea—Mitoxantrone—lymphatic system cancer	0.00983	0.00983	CcSEcCtD
Fludrocortisone—Sweating increased—Fludarabine—lymphatic system cancer	0.00887	0.00887	CcSEcCtD
Fludrocortisone—Vertigo—Mechlorethamine—lymphatic system cancer	0.0088	0.0088	CcSEcCtD
Fludrocortisone—Injury—Bleomycin—lymphatic system cancer	0.0084	0.0084	CcSEcCtD
Fludrocortisone—Neoplasm—Carmustine—lymphatic system cancer	0.0084	0.0084	CcSEcCtD
Fludrocortisone—Haemoglobin—Teniposide—lymphatic system cancer	0.00833	0.00833	CcSEcCtD
Fludrocortisone—Haemorrhage—Teniposide—lymphatic system cancer	0.00829	0.00829	CcSEcCtD
Fludrocortisone—Hyperglycaemia—Fludarabine—lymphatic system cancer	0.00821	0.00821	CcSEcCtD
Fludrocortisone—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00799	0.00799	CcSEcCtD
Fludrocortisone—Infection—Mechlorethamine—lymphatic system cancer	0.00794	0.00794	CcSEcCtD
Fludrocortisone—Ecchymosis—Mitoxantrone—lymphatic system cancer	0.00781	0.00781	CcSEcCtD
Fludrocortisone—Thrombophlebitis—Carmustine—lymphatic system cancer	0.00779	0.00779	CcSEcCtD
Fludrocortisone—Diabetes mellitus—Carmustine—lymphatic system cancer	0.00775	0.00775	CcSEcCtD
Fludrocortisone—Osteoporosis—Methotrexate—lymphatic system cancer	0.00767	0.00767	CcSEcCtD
Fludrocortisone—Multiple fractures—Methotrexate—lymphatic system cancer	0.0074	0.0074	CcSEcCtD
Fludrocortisone—Fracture—Methotrexate—lymphatic system cancer	0.0074	0.0074	CcSEcCtD
Fludrocortisone—Injury—Carmustine—lymphatic system cancer	0.00733	0.00733	CcSEcCtD
Fludrocortisone—Haemoglobin—Fludarabine—lymphatic system cancer	0.00732	0.00732	CcSEcCtD
Fludrocortisone—Haemorrhage—Fludarabine—lymphatic system cancer	0.00729	0.00729	CcSEcCtD
Fludrocortisone—Skin hyperpigmentation—Methotrexate—lymphatic system cancer	0.00723	0.00723	CcSEcCtD
Fludrocortisone—Cardiac failure congestive—Mitoxantrone—lymphatic system cancer	0.00691	0.00691	CcSEcCtD
Fludrocortisone—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.00648	0.00648	CcSEcCtD
Fludrocortisone—Hypertension—Teniposide—lymphatic system cancer	0.00623	0.00623	CcSEcCtD
Fludrocortisone—Muscular weakness—Carmustine—lymphatic system cancer	0.00595	0.00595	CcSEcCtD
Fludrocortisone—Oedema—Teniposide—lymphatic system cancer	0.00589	0.00589	CcSEcCtD
Fludrocortisone—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00589	0.00589	CcSEcCtD
Fludrocortisone—Infection—Teniposide—lymphatic system cancer	0.00585	0.00585	CcSEcCtD
Fludrocortisone—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00569	0.00569	CcSEcCtD
Fludrocortisone—Muscular weakness—Vincristine—lymphatic system cancer	0.00568	0.00568	CcSEcCtD
Fludrocortisone—Convulsion—Fludarabine—lymphatic system cancer	0.0055	0.0055	CcSEcCtD
Fludrocortisone—Myalgia—Fludarabine—lymphatic system cancer	0.0054	0.0054	CcSEcCtD
Fludrocortisone—Haemoglobin—Bleomycin—lymphatic system cancer	0.00537	0.00537	CcSEcCtD
Fludrocortisone—Haemorrhage—Bleomycin—lymphatic system cancer	0.00534	0.00534	CcSEcCtD
Fludrocortisone—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00528	0.00528	CcSEcCtD
Fludrocortisone—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00526	0.00526	CcSEcCtD
Fludrocortisone—Petechiae—Methotrexate—lymphatic system cancer	0.00523	0.00523	CcSEcCtD
Fludrocortisone—Oedema—Fludarabine—lymphatic system cancer	0.00518	0.00518	CcSEcCtD
Fludrocortisone—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00518	0.00518	CcSEcCtD
Fludrocortisone—Infection—Fludarabine—lymphatic system cancer	0.00514	0.00514	CcSEcCtD
Fludrocortisone—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00501	0.00501	CcSEcCtD
Fludrocortisone—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00489	0.00489	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00472	0.00472	CcSEcCtD
Fludrocortisone—Haemoglobin—Carmustine—lymphatic system cancer	0.00469	0.00469	CcSEcCtD
Fludrocortisone—Urticaria—Teniposide—lymphatic system cancer	0.00468	0.00468	CcSEcCtD
Fludrocortisone—Haemorrhage—Carmustine—lymphatic system cancer	0.00466	0.00466	CcSEcCtD
Fludrocortisone—Erythema—Bleomycin—lymphatic system cancer	0.00465	0.00465	CcSEcCtD
Fludrocortisone—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00436	0.00436	CcSEcCtD
Fludrocortisone—Hypersensitivity—Teniposide—lymphatic system cancer	0.00434	0.00434	CcSEcCtD
Fludrocortisone—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00434	0.00434	CcSEcCtD
Fludrocortisone—Asthenia—Teniposide—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Fludrocortisone—Erythema—Carmustine—lymphatic system cancer	0.00406	0.00406	CcSEcCtD
Fludrocortisone—Myalgia—Bleomycin—lymphatic system cancer	0.00396	0.00396	CcSEcCtD
Fludrocortisone—Ecchymosis—Methotrexate—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Fludrocortisone—Neoplasm—Methotrexate—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Fludrocortisone—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Fludrocortisone—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.0038	0.0038	CcSEcCtD
Fludrocortisone—Oedema—Bleomycin—lymphatic system cancer	0.0038	0.0038	CcSEcCtD
Fludrocortisone—Erythema—Mitoxantrone—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Fludrocortisone—Infection—Bleomycin—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Fludrocortisone—Asthenia—Fludarabine—lymphatic system cancer	0.00371	0.00371	CcSEcCtD
Fludrocortisone—Headache—Teniposide—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Fludrocortisone—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Fludrocortisone—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Fludrocortisone—Convulsion—Carmustine—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Fludrocortisone—Hypertension—Carmustine—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Fludrocortisone—Vertigo—Vincristine—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00346	0.00346	CcSEcCtD
Fludrocortisone—Myalgia—Carmustine—lymphatic system cancer	0.00346	0.00346	CcSEcCtD
Fludrocortisone—Convulsion—Vincristine—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Fludrocortisone—Hypertension—Vincristine—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Fludrocortisone—Oedema—Carmustine—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Fludrocortisone—Myalgia—Vincristine—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Fludrocortisone—Infection—Carmustine—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Fludrocortisone—Convulsion—Mitoxantrone—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Fludrocortisone—Hypertension—Mitoxantrone—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Fludrocortisone—Headache—Fludarabine—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Fludrocortisone—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Fludrocortisone—Myalgia—Mitoxantrone—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Fludrocortisone—Oedema—Vincristine—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Fludrocortisone—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Fludrocortisone—Infection—Vincristine—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Fludrocortisone—Oedema—Mitoxantrone—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Fludrocortisone—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Fludrocortisone—Infection—Mitoxantrone—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Fludrocortisone—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Fludrocortisone—Urticaria—Bleomycin—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Fludrocortisone—Insomnia—Carmustine—lymphatic system cancer	0.003	0.003	CcSEcCtD
Fludrocortisone—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Fludrocortisone—Mood swings—Methotrexate—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Fludrocortisone—Insomnia—Vincristine—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Fludrocortisone—Hypersensitivity—Bleomycin—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Fludrocortisone—Asthenia—Bleomycin—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Fludrocortisone—Pancreatitis—Methotrexate—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Fludrocortisone—Urticaria—Mitoxantrone—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Fludrocortisone—Hypersensitivity—Carmustine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Fludrocortisone—Asthenia—Carmustine—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Fludrocortisone—Hypersensitivity—Vincristine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Fludrocortisone—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Fludrocortisone—Asthenia—Vincristine—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Fludrocortisone—Asthenia—Mitoxantrone—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Fludrocortisone—Haemoglobin—Methotrexate—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Fludrocortisone—Haemorrhage—Methotrexate—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Fludrocortisone—Headache—Carmustine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Fludrocortisone—Headache—Vincristine—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Fludrocortisone—Headache—Mitoxantrone—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Fludrocortisone—Erythema—Methotrexate—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Fludrocortisone—Vertigo—Methotrexate—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Fludrocortisone—Convulsion—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Fludrocortisone—Myalgia—Methotrexate—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Fludrocortisone—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Fludrocortisone—Infection—Methotrexate—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Fludrocortisone—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Fludrocortisone—Insomnia—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Fludrocortisone—Urticaria—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Fludrocortisone—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Fludrocortisone—Asthenia—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Fludrocortisone—Headache—Methotrexate—lymphatic system cancer	0.000962	0.000962	CcSEcCtD
